H2020
AML-VACCiN
Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia
- Programme
- Horizon 2020
- Started
- Ends
- Duration
- 57 months
- Total cost
- EUR 8,278,716
- EU contribution
- EUR 6,001,482
- Participants
- 20 from 8 countries
- Topic
- H2020_PHC-14-2015
- Grant agreement
- 667713
Coordinated by Stichting Amsterdam Umc (NLNetherlands).
Consortium
EU contribution per participant as the open data of CORDIS states it; for a participant with linked third parties it may include their share, and a participant whose amount the data does not hold or cannot make consistent shows Not stated. A participant who left the project is not listed; see the history below.
| Organisation | Country | Role | EU contribution | Recognised by |
|---|---|---|---|---|
| Stichting Amsterdam Umc | NLNetherlands | Coordinator | EUR 364,640 | known name (0.95) |
| Biontech Innovative Manufacturing Services GmbH | DEGermany | Participant | EUR 550,111 | PIC (1.00) |
| Immatics Biotechnologies GmbH | DEGermany | Participant | EUR 1,300,650 | PIC (1.00) |
| Linical Europe GmbH | DEGermany | Third party | Not stated | PIC (1.00) |
| Technische Universitaet Dresden | DEGermany | Participant | EUR 0 | PIC (1.00) |
| Universitaet Leipzig | DEGermany | Participant | EUR 82,320 | PIC (1.00) |
| Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz | DEGermany | Participant | EUR 82,320 | PIC (1.00) |
| Universitatsklinikum Bonn | DEGermany | Participant | EUR 82,320 | known name (0.95) |
| Linical Spain Slu | ESSpain | Third party | Not stated | PIC (1.00) |
| Helsingin Yliopisto | FIFinland | Participant | EUR 82,320 | known name (0.95) |
| Linical Accelovance Europe Ltd | GBUnited Kingdom | Third party | Not stated | PIC (1.00) |
| Academisch Ziekenhuis Groningen | NLNetherlands | Participant | EUR 82,320 | PIC (1.00) |
| Dcprime BV | NLNetherlands | Participant | EUR 2,002,539 | PIC (1.00) |
| Linical Netherlands B.V. | NLNetherlands | Participant | EUR 1,022,313 | PIC (1.00) |
| Stichting Vu | NLNetherlands | Participant | EUR 0 | known name (0.95) |
| Helse Bergen Hf | NONorway | Participant | EUR 82,320 | known name (0.95) |
| Universitetet i Bergen | NONorway | Participant | EUR 184,989 | known name (0.95) |
| Linical Accelovance Romania SRL | RORomania | Third party | Not stated | PIC (1.00) |
| Region Uppsala | SESweden | Third party | Not stated | known name (0.95) |
| Uppsala Universitet | SESweden | Participant | EUR 82,320 | known name (0.95) |
Changes of the consortium
First seen on with 20 participants from 8 countries.
A snapshot of each project's members is taken once a month; a change is recorded when a snapshot differs from the one before. A project with no change listed has had the same members since it was first observed.
Project page on CORDIS (opens in new tab)
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them.
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.